canrenone has been researched along with spironolactone in 142 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 83 (58.45) | 18.7374 |
| 1990's | 15 (10.56) | 18.2507 |
| 2000's | 16 (11.27) | 29.6817 |
| 2010's | 23 (16.20) | 24.3611 |
| 2020's | 5 (3.52) | 2.80 |
| Authors | Studies |
|---|---|
| Haga, N; Ishibashi, M; Itoh, T; Kamata, S; Matsui, T; Nakamura, M; Odaguchi, K; Shimizu, T; Suzuki, T; Yamada, F | 1 |
| Chinn, LJ; Desai, BN; Salamon, KW | 1 |
| Aumelas, A; Auzou, G; Claire, M; Faraj, H; Grassy, G; Rondot, A | 1 |
| Aubry-Marais, F; Aupetit, B; Duchier, J; Legrand, JC | 1 |
| Karlmar, KE | 1 |
| Claire, M; Corvol, P; Menard, J; Michaud, A; Rafestin-Oblin, ME; Roth-Meyer, C | 1 |
| Colby, HD; Greiner, JW; Kramer, RE; Rumbaugh, RC | 1 |
| Hofmann, LM; Pedrera, HA; Suleymamov, OD | 1 |
| Wachter, C; Wood, WG | 1 |
| Al-Dujaili, EA; Huston, GJ | 1 |
| Hettiarachchi, J; Ramsay, LE | 2 |
| Hitzenberger, G; Horwatitsch, H; Rameis, H | 1 |
| Erkkola, R; Lammintausta, R | 1 |
| Bartle, WR; Coates, PE; Fisher, MM; Louman, FJ | 1 |
| Ambrosius, D; Neurath, GB | 1 |
| Clark, EC; Müller, DG; van der Merwe, PJ | 1 |
| Erking, W; Lücker, PW; Stöcker, KP; Wetzelsberger, K | 1 |
| Jaeger, H; Rosenthal, J; Specker, M | 1 |
| Abshagen, U; L'age, M; Spörl, S | 1 |
| Aupetit, B; Duchier, J; Legrand, JC | 1 |
| Del Mastro, S; Lucchelli, PD; Monarca, A; Sega, R | 1 |
| Erbler, HC | 1 |
| Asbury, M; Harrison, I; Ramsay, L; Shelton, J; Tidd, M | 1 |
| Brown, EA; Chinn, LJ; Karim, A; Mizuba, SS | 1 |
| Branch, R; Jackson, L; Levine, D; Ramsay, L | 1 |
| Asbury, M; Harrison, I; Ramsay, L; Shelton, J | 1 |
| Harrison, IR; Ramsay, LE; Shelton, JR | 1 |
| Danielson, K; Melander, A; Scherstén, B; Thulin, T; Wåhlin, E | 1 |
| Palmer, RF; Ramsay, LE; Shelton, JR; Tidd, MJ | 1 |
| Caminos-Torres, R; Ma, L; Snyder, PJ | 1 |
| Koch, K; Neubert, P | 1 |
| Karim, A; Phelps, DL | 1 |
| Abshagen, U; Kuhlmann, J; Rennekamp, H | 1 |
| Juhos, E; Radó, JP; Sawinsky, I | 2 |
| Bodrogi, L; Fehér, T; Váradi, A | 1 |
| Huston, GJ; Turner, P | 1 |
| Cheng, SC; Harding, BW; Sadee, W; Suzuki, K | 1 |
| Chao, AY; Karim, A; Mattes, K; Nicholova, B; Sanvordeker, DR; Zagarella, J | 1 |
| Bertharion, JJ; Bieder, A; Gaillot, J; Portal, A; Rodary, C | 1 |
| Frenkl, R; Szeberényi, S | 1 |
| Chamberlain, J; Collins, WT; Tidd, MJ | 1 |
| Erbler, HC; Hilfenhaus, M | 1 |
| Klaassen, CD | 1 |
| Kozma, C; Nagy, O; Radó, JP; Szende, L; Takó, J | 1 |
| Dooley, M; Hribar, J; Karim, A; Zagarella, J | 1 |
| Baltes, BJ; Chao, A; Hutsell, TC; Karim, A; Zagarella, J | 1 |
| Dooley, M; Hutsell, TC; Karim, A; Zagarella, J | 1 |
| Kourounakis, PN; Pouskoulelis, GP; Rekka, E | 1 |
| de Kloet, ER; Sutanto, W | 1 |
| Blöchl-Daum, B; Eichler, HG; Freissmuth, M; Loew, D; Schütz, W; Tuisl, E | 1 |
| Gentilini, P | 1 |
| Foukaridis, GN | 1 |
| Christiaens, L; De Graeve, J; Genard, P; Lomba-Pignon, MR; Palem-Vliers, M | 1 |
| Lewicka, S; Vecsei, P; Weindel, K | 1 |
| Gadsden, RH; Pleasants, RA; Porter, RS; Williams, DM | 1 |
| MacKie, R; McInnes, GT; McLellan, AR; Rentoul, J | 1 |
| Andriulli, A; Armanini, D; Arrigoni, A; Buzzetti, G; Gindro, T; Karbowiak, I | 1 |
| Felber, JP; Locatelli, L; Ramelet, AA; Rey, FO; Valterio, C | 1 |
| Nuss, U; Strobel, K; Vergin, H | 1 |
| Merkus, FW; Overdiek, HW | 1 |
| Colby, HD; O'Donnell, JP; Sherry, JH | 1 |
| Boucher, RC; Gatzy, JT; Knowles, MR | 1 |
| Hermens, WA; Merkus, FW; Overdiek, JW | 1 |
| Buse, M; Casals-Stenzel, J; Losert, W | 1 |
| Hermens, WA; Merkus, FW; Overdiek, HW | 1 |
| Nagy, O; Radó, JP; Szende, L; Takó, J | 1 |
| Mühlberg, W; Platt, D | 1 |
| Finotti, P; Palatini, P | 1 |
| Abshagen, U; Horn, HJ; Mühlberg, W; Platt, D; Schmitt-Rüth, R; Vollmar, J | 1 |
| Clarke, JM; Harrison, IR; McInnes, GT; Perkins, RM; Shelton, JR | 1 |
| Bourne, DW; Ho, PC; Smithurst, BA; Triggs, EJ | 1 |
| Bourne, DW; Heazlewood, V; Ho, PC; Triggs, EJ | 1 |
| Jakobs, U; Karras, J; Krause, W | 1 |
| Karras, J; Krause, W; Seifert, W | 1 |
| Liedholm, H; Lindholm, L; Melander, A; Thulin, T; Wåhlin-Boll, E | 1 |
| Erbler, HC; Weissenborn, U | 1 |
| Rahn, KH | 1 |
| Cilissen, J; Merkus, FW; Overdiek, JW; Zuidema, J | 1 |
| Janata, V; Jirka, J; Martínek, V; Stríbrná, J | 1 |
| Claire, M; Corvol, P; Geering, K; Oblin, ME; Rossier, B | 1 |
| Harrison, IR; McInnes, GT; Perkins, RM; Shelton, JR | 1 |
| Hitzenberger, G; Nuss, U; Schwarzländer, F; Strobel, K; Vergin, H; Weigand, W | 1 |
| Anderton, JL; Bell, GM; Fananapazir, L | 1 |
| Carruthers, SG; Dujovne, CA | 1 |
| Claire, M; Corvol, P; Fournex, R; Michaud, A; Peterfalvi, M; Rousseau, G; Torelli, V | 1 |
| Görlitzer, K; Moormann, P; Pollow, K; Schaffrath, M | 1 |
| Campíns-Falcó, P; Herráez-Hernández, R; Soriano-Vega, E | 1 |
| Colby, HD; Los, LE | 1 |
| Jankowski, A; Lamparczyk, H; Skorek-Jankowska, A | 1 |
| Andriuoli, G; Calignano, A; Cirino, G; Mancuso, F; Pinto, A; Sorrentino, L; Sorrentino, R | 1 |
| Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P | 1 |
| Eichinger, A; Mahr, G; Martens, H; Metz, R; Nitsche, V; Vergin, H | 1 |
| Eichinger, A; Mahr, G; Metz, R; Nitsche, V; Vergin, H | 1 |
| Eber, B; Emmanuilidis, K; Müller, C; Steimer, W | 1 |
| Frömter, E; Rabe, A | 1 |
| Arias, JJ; Hernández, O; Jiménez, AI; Jiménez, F; Martín, E | 1 |
| Alfieri, C; Autore, G; Calignano, A; Cirino, G; d'Emmanuele de Villa Bianca, R; Pinto, A; Sorrentino, L; Sorrentino, R; Vanasia, M | 1 |
| Eber, B; Müller, C; Steimer, W | 1 |
| Dasgupta, A; Datta, P; Saffer, H; Wells, A | 1 |
| Sanderson, JE | 1 |
| Baez, J; Byng, G; Laakso, JA; Mocek, UM; Preisig, CL; Wang, PT | 1 |
| Dasgupta, A; Datta, P | 1 |
| ANDERSON, ML; BOUSKA, DJ; KAGAWA, CM | 1 |
| Fumeaux, Z; Mach, F; Martin, PY; Perneger, T; Rossier, M; Saudan, P; Schnetzler, B; Stoermann, C | 1 |
| Brunette, MG; Couchourel, D; Leclerc, M | 1 |
| Collier, PS; McElnay, JC; Millership, JS; Sandall, JM | 1 |
| Chen, Y; Dong, H; Tian, Y; Xu, F; Zhang, Z | 1 |
| Dasgupta, A; Datta, P; Kang, E | 1 |
| Dasgupta, A; Tso, G; Wells, A | 1 |
| Bassani, JW; Costa, AR; Ferreira, AT; França, JP; Medei, E; Nascimento, JH; Oshiro, ME; Ricardo, RA; Smaili, S; Torres, LB; Tucci, PJ | 1 |
| Bagrov, AY; Cooper, CJ; El-Okdi, N; Elkareh, J; Fedorova, OV; Gohara, S; Gupta, S; Haller, S; Malhotra, D; Periyasamy, SM; Shapiro, JI; Shidyak, A; Taleb, M; Tian, J; Xie, Z | 1 |
| Bowalgaha, K; Knights, KM; Miners, JO | 1 |
| Albu, F; David, V; Medvedovici, A; Sora, DI; Udrescu, S | 1 |
| Armbruster, D; Cooper, KC; Dasgupta, A; DeFrance, A; Petty, D | 1 |
| Dasgupta, A; Johnson, MJ | 1 |
| Agostoni, P; Boccanelli, A | 1 |
| Gheorghe, MC; Medvedovici, A; Sârbu, C; Sora, ID; Voicu, V | 1 |
| Ramsay, LE; Shelton, JR; Tidd, MJ; Wilkinson, D | 1 |
| Chen, H; Feng, H; Li, Y; Tang, H; Zhang, B | 1 |
| Dasgupta, A; Johnson, MJ; Sengupta, TK | 1 |
| Bolorunduro, O; Chatterjee, S; Lichstein, E; Moeller, C; Moskovits, N; Mukherjee, D; Shah, N | 1 |
| Chen, YQ; Deng, SB; Du, JL; Hu, LJ; She, Q | 1 |
| Cleare, AJ; Juruena, MF; Lightman, S; Papadopoulos, AS; Pariante, CM; Poon, L | 1 |
| Armanini, D; Bordin, L; Clari, G; Donà, G; Sabbadin, C | 1 |
| Bagrov, AY; Bagrov, KA; Emelianov, IV; Fedorova, OV; Frolova, EV; Grigorova, YN; Juhasz, O; Konradi, AO; Lakatta, EG; Marshall, CA; Wei, W | 1 |
| Bernhardt, R; Brixius-Anderko, S; Hannemann, F; Hobler, A; Müller, AR; Schiffer, L; Zapp, J | 1 |
| Chen, A; Huang, Y; Li, L; Zhang, G; Zhang, H; Zhao, W | 1 |
| Channar, PA; El-Seedi, H; Faisal, M; Larik, FA; Mehfooz, H; Saeed, A; Shahzad, D | 1 |
| Aro, R; Herodes, K; Kipper, K; Kõrgvee, LT; Lass, J; Takkis, K; Varendi, H | 1 |
| Claggett, B; de Denus, S; Desai, AS; Jutras, M; Lavoie, J; Leclair, G; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Solomon, SD | 1 |
| Abdallah, FF; Abdelaleem, EA; Ali, NW; Emam, AA; Naguib, IA | 2 |
| Baker, WL; de Denus, S; Korol, S; Mottet, F; Perreault, S; White, M | 1 |
| Cunha-Filho, M; Ferreira, LA; Ferreira-Nunes, R; Gelfuso, GM; Gratieri, T | 1 |
| Bernhardt, R; Hartmann, MF; Reincke, M; Wudy, SA | 1 |
| Atar, D; Clark, AL; Frankenstein, L; Fröhlich, H; Jensen, K; Katus, HA; Naci, H; Nee, P; Seide, S; Seiz, M; Täger, T; Uhlmann, L | 1 |
| Behar-Cohen, F; Dahmana, N; Gabriel, D; Gurny, R; Kalia, YN; Kowalczuk, L | 1 |
| Hsueh, TP; Tsai, TH | 1 |
| Bolignano, D; Chung, EY; Natale, P; Navaneethan, SD; Palmer, SC; Ruospo, M; Strippoli, GF | 1 |
| Anderson, P; Bushman, L; Castro, CRV; Cattani, VB; Eksterman, L; Estrela, R; Grinsztejn, B; Jalil, EM; Monteiro, L; Torres, T; Veloso, VG; Wagner Cardoso, S; Wilson, E | 1 |
9 review(s) available for canrenone and spironolactone
| Article | Year |
|---|---|
Spirolactones: clinical and pharmacologic studies.
Topics: Aldosterone; Animals; Binding, Competitive; Canrenoic Acid; Canrenone; Diuresis; Humans; Hyperaldosteronism; Hypertension; In Vitro Techniques; Kidney; Mineralocorticoid Receptor Antagonists; Pregnadienes; Protein Binding; Rats; Receptors, Cell Surface; Spironolactone | 1977 |
Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects.
Topics: Addison Disease; Adrenal Cortex Hormones; Animals; Brain Chemistry; Canrenone; Drug Design; Hippocampus; Humans; Hyperaldosteronism; Ligands; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Rats; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Receptors, Steroid; Spironolactone; Structure-Activity Relationship | 1991 |
Mechanism of the antimineralocorticoid effects of spirolactones.
Topics: Aldosterone; Animals; Anura; Canrenoic Acid; Canrenone; Cattle; Guinea Pigs; Humans; Male; Mineralocorticoid Receptor Antagonists; Rats; Receptors, Steroid; Spironolactone; Veratrum Alkaloids | 1981 |
Eplerenone is not superior to older and less expensive aldosterone antagonists.
Topics: Canrenone; Cause of Death; Cost-Benefit Analysis; Drug Costs; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Survival Rate; Treatment Outcome | 2012 |
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone; Ventricular Remodeling | 2013 |
Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives.
Topics: Aldosterone; Androstadienes; Androstenes; Animals; Canrenone; Chloranil; Dehydroepiandrosterone; Eplerenone; Humans; Molecular Structure; Receptors, Mineralocorticoid; Spironolactone | 2017 |
A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
Topics: Blood Glucose; Canrenone; Eplerenone; Glycated Hemoglobin; Homeostasis; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2017 |
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Topics: Canrenone; Diuretics; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Network Meta-Analysis; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2020 |
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone | 2020 |
19 trial(s) available for canrenone and spironolactone
| Article | Year |
|---|---|
Spironolactone response related to plasma canrenone concentration [proceedings].
Topics: Canrenone; Humans; Pregnadienes; Spironolactone | 1979 |
[Biological availability of spironolactone in two different galenic forms (author's transl)].
Topics: Adult; Biological Availability; Canrenone; Humans; Male; Spironolactone; Time Factors | 1979 |
Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Topics: Adult; Biological Availability; Canrenone; Drug Interactions; Humans; Kinetics; Male; Neomycin; Spironolactone | 1979 |
Spironolactone and potassium canrenoate in normal man.
Topics: Canrenoic Acid; Canrenone; Clinical Trials as Topic; Humans; Male; Potassium; Pregnadienes; Sodium; Spironolactone; Time Factors | 1976 |
Plasma uric acid and spironolactone response in healthy subjects.
Topics: Biological Availability; Canrenone; Creatinine; Humans; Potassium; Sodium; Spironolactone; Tablets; Uric Acid | 1977 |
Antagonism of fludrocortisone by spironolactone and canrenone.
Topics: Adolescent; Adult; Aged; Canrenone; Dose-Response Relationship, Drug; Fludrocortisone; Humans; Male; Middle Aged; Pregnadienes; Spironolactone | 1976 |
Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach.
Topics: Adult; Canrenone; Diuresis; Drug Combinations; Drug Evaluation; Electrolytes; Furosemide; Humans; Male; Spironolactone; Therapeutic Equivalency | 1991 |
Lack of effect of spironolactone on hair shaft diameter in hirsute females.
Topics: Androgens; Canrenone; Double-Blind Method; Female; Gonadotropins, Pituitary; Hair; Hirsutism; Humans; Prolactin; Randomized Controlled Trials as Topic; Spironolactone | 1989 |
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Canrenone; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Pregnadienes; Random Allocation; Receptors, Androgen; Recurrence; Spironolactone; Testosterone; Time Factors | 1989 |
Lack of endocrine systemic side effects after topical application of spironolactone in man.
Topics: 17-alpha-Hydroxyprogesterone; Administration, Topical; Adult; Androgens; Androstane-3,17-diol; Canrenone; Endocrine Glands; Humans; Hydroxyprogesterones; Male; Salivary Glands; Spironolactone; Testosterone | 1988 |
[Bioavailability studies of two spironolactone-preparations (author's transl)].
Topics: Adolescent; Adult; Biological Availability; Canrenone; Humans; Kinetics; Male; Spectrometry, Fluorescence; Spironolactone | 1981 |
Spironolactone in thiazide-induced hypokalaemia: variable response between patients.
Topics: Adult; Aldosterone; Benzothiadiazines; Canrenone; Diuretics; Electrolytes; Female; Humans; Hypokalemia; Male; Middle Aged; Potassium; Sodium Chloride Symporter Inhibitors; Spironolactone | 1981 |
Comparison of single and divided daily dose spironolactone in the control of hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Canrenone; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Pregnadienes; Spironolactone | 1981 |
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclodextrins; Diuresis; Diuretics; Female; Humans; Liver Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome; Water-Electrolyte Balance | 1997 |
Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
Topics: Administration, Oral; Adult; Analysis of Variance; Canrenone; Cross-Over Studies; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Therapeutic Equivalency; Time Factors | 1997 |
Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Topics: Adult; Area Under Curve; Canrenone; Chromatography, High Pressure Liquid; Diuretics; Furosemide; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Therapeutic Equivalency | 1998 |
Safety of low-dose spironolactone administration in chronic haemodialysis patients.
Topics: Adult; Aged; Aldosterone; Canrenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Renal Dialysis; Spironolactone | 2003 |
The role of mineralocorticoid receptor function in treatment-resistant depression.
Topics: Canrenone; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pituitary-Adrenal System; Prednisolone; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Saliva; Single-Blind Method; Spironolactone | 2013 |
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
Topics: Adult; Anti-HIV Agents; Brazil; Canrenone; Estradiol; Female; HIV Infections; Humans; Male; Spironolactone; Transgender Persons; Young Adult | 2023 |
114 other study(ies) available for canrenone and spironolactone
| Article | Year |
|---|---|
Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives.
Topics: Adrenalectomy; Animals; Kidney; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred Strains; Receptors, Androgen; Receptors, Mineralocorticoid; Receptors, Progesterone; Receptors, Steroid; Structure-Activity Relationship | 1987 |
A structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity.
Topics: Chemical Phenomena; Chemistry; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Molecular Conformation; Receptors, Mineralocorticoid; Receptors, Steroid; Spironolactone; Structure-Activity Relationship | 1981 |
Synthesis of new 11 beta-substituted spirolactone derivatives. Relationship with affinity for mineralocorticoid and glucocorticoid receptors.
Topics: Adrenalectomy; Aldosterone; Animals; Dexamethasone; Kidney; Rabbits; Receptors, Glucocorticoid; Spironolactone; Structure-Activity Relationship | 1993 |
[Antialdosterones and enzymes of the adrenal gland].
Topics: Adrenal Cortex Hormones; Adrenal Glands; Animals; Canrenone; Ducks; Humans; Hydroxylation; Mineralocorticoid Receptor Antagonists; Mitochondria; Spironolactone | 1978 |
Assay and properties of 18-hydroxylation of endogenous and exogenous corticosterone in rat adrenals. Evidence for heterogeneity of 18-hydroxylase activity.
Topics: Adrenal Glands; Animals; Canrenoic Acid; Canrenone; Corticosterone; Gas Chromatography-Mass Spectrometry; Male; Mitochondria; NADPH-Ferrihemoprotein Reductase; Potassium Chloride; Rats; Spironolactone; Steroid Hydroxylases | 1979 |
Relation of canrenone to the actions of spironolactone on adrenal cytochrome P-450 dependent enzymes.
Topics: Adrenal Glands; Animals; Canrenone; Cytochrome P-450 Enzyme System; Ethylmorphine-N-Demethylase; Guinea Pigs; Male; Microsomes; Mitochondria; Mixed Function Oxygenases; Pregnadienes; Spironolactone; Steroid 11-beta-Hydroxylase; Steroid 21-Hydroxylase | 1978 |
Aldosterone antagonism studies in the rhesus monkey.
Topics: Administration, Oral; Aldosterone; Animals; Canrenone; Diuresis; Dose-Response Relationship, Drug; Female; Haplorhini; Hydrochlorothiazide; Injections, Intramuscular; Macaca mulatta; Mineralocorticoid Receptor Antagonists; Potassium; Sodium; Spironolactone | 1977 |
A critical appraisal of a further three new commercial digoxin radioimmunoassay kits with reference to cross-reacting substances.
Topics: Blood Proteins; Canrenone; Cross Reactions; Digitoxin; Digoxin; Evaluation Studies as Topic; Furosemide; Humans; Radioimmunoassay; Reagent Kits, Diagnostic; Spironolactone | 1979 |
A comparison of some extra-renal effects of spironolactone and canrenone.
Topics: Aldosterone; Canrenone; Humans; Male; Membrane Potentials; Middle Aged; Mineralocorticoid Receptor Antagonists; Pregnadienes; Pressure; Rectum; Spironolactone; Time Factors | 1979 |
Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.
Topics: Aldosterone; Canrenone; Female; Humans; Potassium; Pregnancy; Renin; Sodium; Spironolactone; Time Factors | 1979 |
High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Male; Pregnadienes; Spectrometry, Fluorescence; Spironolactone | 1979 |
Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
Topics: Biological Availability; Canrenone; Chromatography, Thin Layer; Humans; Male; Pregnadienes; Spectrometry, Fluorescence; Spironolactone | 1979 |
[Relative bioavailability of a new spironolactone preparation (author's transl)].
Topics: Adult; Biological Availability; Canrenone; Humans; Kinetics; Middle Aged; Spironolactone | 1979 |
[Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Topics: Adult; Biological Availability; Canrenoic Acid; Canrenone; Female; Humans; Male; Spironolactone; Time Factors | 1979 |
Non-interaction of spironolactone medication and cortisol metabolism in man.
Topics: Canrenoic Acid; Canrenone; Drug Interactions; Humans; Hydrocortisone; Liver Diseases; Spironolactone | 1978 |
[Effect of spironolactones on aldosterone synthesis and adrenal metabolism].
Topics: Adrenal Glands; Aldosterone; Animals; Canrenoic Acid; Canrenone; Ducks; Hydroxylation; Mineralocorticoid Receptor Antagonists; Mitochondria; Mitochondria, Liver; Oxidative Phosphorylation; Sheep; Spironolactone; Steroid Hydroxylases | 1978 |
[Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
Topics: Adult; Biological Availability; Canrenone; Capsules; Female; Humans; Male; Spironolactone; Tablets | 1978 |
Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Animals; Canrenone; Dose-Response Relationship, Drug; Male; Pregnadienes; Rats; Renin; Spironolactone; Time Factors; Water-Electrolyte Balance | 1979 |
Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
Topics: Animals; Canrenone; Chemical Phenomena; Chemistry; Desoxycorticosterone; Humans; Penicillium; Pregnadienes; Rats; Spironolactone; Structure-Activity Relationship | 1977 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseases; Male; Middle Aged; Pregnadienes; Serum Albumin; Spironolactone | 1977 |
Spironolactone and canrenoate-K: relative potency at steady state.
Topics: Administration, Oral; Adult; Canrenoic Acid; Canrenone; Dose-Response Relationship, Drug; Fludrocortisone; Humans; Male; Potassium; Pregnadienes; Sodium; Solutions; Spironolactone; Tablets; Therapeutic Equivalency; Time Factors | 1977 |
Enhancement by food of canrenone bioavailability from spironolactone.
Topics: Administration, Oral; Adult; Biological Availability; Canrenone; Food; Humans; Kinetics; Male; Pregnadienes; Spironolactone; Time Factors | 1977 |
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Canrenone; Dose-Response Relationship, Drug; Humans; Male; Pregnadienes; Solutions; Spironolactone; Suspensions; Tablets | 1977 |
Gynecomastia and semen abnormalities induced by spironolactone in normal men.
Topics: Adult; Canrenoic Acid; Canrenone; Estradiol; Follicle Stimulating Hormone; Gynecomastia; Humans; Luteinizing Hormone; Male; Pituitary Gland; Sperm Motility; Spermatozoa; Spironolactone; Testis; Testosterone | 1977 |
Simultaneous automated determination of spironolactone metabolites in serum.
Topics: Autoanalysis; Canrenoic Acid; Canrenone; Humans; Methods; Spectrometry, Fluorescence; Spironolactone; Time Factors | 1977 |
Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
Topics: Adult; Canrenone; Female; Humans; Milk, Human; Pregnadienes; Spironolactone; Time Factors | 1977 |
Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.
Topics: Administration, Oral; Adult; Bile; Canrenoic Acid; Canrenone; Digoxin; Feces; Female; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Spironolactone; Tritium | 1976 |
Paradoxical reversal of the suppressed potassium secretion during treatment with combinations of antikaluretic agents (spironolactone, canrenone, triamterene, amiloride); a possible site of action in Henle's loop.
Topics: Amiloride; Canrenone; Humans; Kidney Tubules; Liver Cirrhosis; Loop of Henle; Male; Middle Aged; Potassium; Pregnadienes; Pyrazines; Sodium; Spironolactone; Triamterene | 1976 |
Simple gas chromatographic method with flame ionization detection for the determination of aldadiene in human urine.
Topics: Canrenone; Chromatography, Gas; Hot Temperature; Humans; Pregnadienes; Spironolactone | 1976 |
Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
Topics: Adenoma; Adrenal Cortex; Adrenal Gland Neoplasms; Adrenal Glands; Aldosterone; Animals; Canrenoic Acid; Canrenone; Cattle; Cytochrome P-450 Enzyme System; Humans; Hyperplasia; Mitochondria; Oxidation-Reduction; Pregnadienes; Spectrum Analysis; Spironolactone; Steroid Hydroxylases | 1976 |
In vitro and in vivo availability of spironolactone from oral dosage forms.
Topics: Animals; Biological Availability; Canrenone; Dogs; Drug Combinations; Drug Compounding; Drug Interactions; Excipients; Female; Half-Life; Hardness Tests; Hydrochlorothiazide; Kinetics; Solubility; Solutions; Spironolactone; Tablets | 1976 |
Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
Topics: Amiloride; Ascites; Canrenone; Diuresis; Diuretics; Drug Synergism; Drug Therapy, Combination; Humans; Liver Cirrhosis; Natriuresis; Potassium; Spironolactone; Triamterene | 1976 |
[Aspects of the physiologic bioavailability of spironolactone and canrenone].
Topics: Biological Availability; Canrenone; Humans; Pregnadienes; Spironolactone | 1976 |
Enzyme inducing effect of muscular exertion in the rat.
Topics: Animals; Canrenone; Dihydrotestosterone; Dose-Response Relationship, Drug; Enzyme Induction; Hexobarbital; Male; Metabolic Clearance Rate; Muscle Contraction; Physical Exertion; Rats; Sleep; Spironolactone; Swimming | 1976 |
A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
Topics: Adolescent; Adult; Biological Availability; Canrenone; Chemistry, Pharmaceutical; Humans; Male; Methods; Solubility; Spironolactone; Tablets; Time Factors | 1976 |
Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolyte
Topics: Aldosterone; Animals; Canrenone; Electrolytes; Male; Pregnadienes; Rats; Renin; Spironolactone | 1975 |
Effect of spironolactone on the distribution of mercury.
Topics: Animals; Bile; Canrenone; Male; Mercury; Mercury Radioisotopes; Rats; Spironolactone; Time Factors | 1975 |
Application of a simple fluorometric method on absorption of canrenone.
Topics: Canrenone; Capsules; Fluorometry; Hydrocortisone; Pregnadienes; Spironolactone; Tablets | 1976 |
Spironolactone. I. Disposition and metabolism.
Topics: Adult; Canrenone; Drug Stability; Erythrocytes; Feces; Half-Life; Humans; In Vitro Techniques; Male; Protein Binding; Spironolactone; Time Factors | 1976 |
Spironolactone. II. Bioavailability.
Topics: Administration, Oral; Adult; Biological Availability; Canrenone; Humans; Male; Solubility; Solutions; Spironolactone; Tablets; Time Factors | 1976 |
Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Topics: Adult; Beverages; Canrenone; Drug Administration Schedule; Food; Half-Life; Humans; Male; Pregnadienes; Spironolactone; Tablets; Time Factors | 1976 |
Interaction of spironolactone with mercury. A possible molecular mechanism.
Topics: Animals; Canrenone; Feces; Female; Mercury; Mercury Poisoning; Rats; Rats, Sprague-Dawley; Spironolactone | 1992 |
Spironolactone and canrenoate: different antialdosteronic diuretic agents.
Topics: Ascites; Canrenoic Acid; Canrenone; Humans; Liver Cirrhosis; Recurrence; Spironolactone | 1991 |
Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
Topics: Canrenone; Cross Reactions; Digoxin; Half-Life; Humans; Iodine Radioisotopes; Pregnadienes; Radioimmunoassay; Spironolactone | 1990 |
Discovery of a natural spirolactone derivative in man and animal.
Topics: Animals; Canrenone; Chromatography, Gas; Chromatography, High Pressure Liquid; Humans; Pregnadienes; Spironolactone | 1985 |
Comparative dose-effect studies with four C-17-spirosteroidal mineralocorticoid synthesis inhibitors.
Topics: Aldosterone; Analysis of Variance; Animals; Canrenone; Male; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Oxazoles; Pregnadienes; Rats; Rats, Inbred Strains; Spiro Compounds; Spironolactone; Zona Glomerulosa | 1989 |
Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
Topics: Adult; Canrenone; Cross Reactions; Digoxin; Humans; Immunoassay; Immunoenzyme Techniques; Male; Radioimmunoassay; Spironolactone | 1989 |
[Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Topics: Administration, Oral; Adult; Bendroflumethiazide; Biological Availability; Canrenone; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Therapy, Combination; Female; Humans; Kinetics; Male; Mineralocorticoid Receptor Antagonists; Potassium; Sodium; Spectrometry, Fluorescence; Spironolactone | 1986 |
Influence of food on the bioavailability of spironolactone.
Topics: Adolescent; Adult; Biological Availability; Canrenone; Fasting; Female; Food; Humans; Kinetics; Male; Middle Aged; Spironolactone | 1986 |
Separation of spironolactone and its biologically active sulfur-containing metabolites by high-performance liquid chromatography.
Topics: Animals; Canrenone; Chromatography, High Pressure Liquid; Guinea Pigs; Male; Mass Spectrometry; Spironolactone | 1986 |
Aldosterone metabolism and transepithelial potential difference in normal and cystic fibrosis subjects.
Topics: Adult; Aldosterone; Canrenone; Cystic Fibrosis; Electrophysiology; Epithelium; Female; Humans; Male; Nose; Rectum; Reference Values; Spironolactone | 1985 |
Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography.
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Spectrophotometry, Ultraviolet; Spironolactone | 1985 |
Progestogens with antimineralocorticoid activity.
Topics: Adrenalectomy; Aldosterone; Androstadienes; Androstenes; Animals; Canrenoic Acid; Canrenone; Cyproterone; Dose-Response Relationship, Drug; Male; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Norethindrone; Norgestrel; Norpregnenes; Potassium; Progesterone; Progesterone Congeners; Rats; Rats, Inbred Strains; Sodium; Spironolactone | 1985 |
New insights into the pharmacokinetics of spironolactone.
Topics: Absorption; Administration, Oral; Adult; Biotransformation; Canrenone; Half-Life; Humans; Kinetics; Male; Spironolactone | 1985 |
Use of a simple fluorometric 11-hydroxycorticosteroids assay in the assessment of spironolactone-metabolite level in plasma and urine.
Topics: Canrenoic Acid; Canrenone; Dose-Response Relationship, Drug; Humans; Hydrocortisone; Spironolactone; Time Factors | 1974 |
[Drug treatment in the elderly: special aspects of diuretics (author's transl)].
Topics: Age Factors; Aged; Canrenone; Diuretics; Humans; Kinetics; Spironolactone; Triamterene | 1982 |
Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
Topics: 4-Nitrophenylphosphatase; Animals; Canrenoic Acid; Canrenone; Guinea Pigs; In Vitro Techniques; Ouabain; Potassium; Pregnadienes; Protein Binding; Receptors, Drug; Sodium-Potassium-Exchanging ATPase; Spironolactone | 1981 |
The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
Topics: Aged; Aging; Blood Proteins; Canrenone; Chromatography, High Pressure Liquid; Disease; Erythrocyte Count; Female; Fluorometry; Humans; Kinetics; Middle Aged; Pregnadienes; Protein Binding; Spironolactone; Time Factors | 1984 |
Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia.
Topics: Adult; Canrenone; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Metolazone; Mineralocorticoid Receptor Antagonists; Potassium; Spironolactone | 1984 |
Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
Topics: Adult; Age Factors; Aged; Biotransformation; Canrenone; Female; Humans; Hydrolysis; Male; Middle Aged; Pregnadienes; Protein Binding; Spectrometry, Fluorescence; Spironolactone; Ultrafiltration | 1984 |
Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Topics: Administration, Oral; Adult; Biotransformation; Canrenone; Chromatography, High Pressure Liquid; Female; Humans; Hydrolysis; Kinetics; Male; Pregnadienes; Spectrometry, Fluorescence; Spironolactone | 1984 |
Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Topics: Administration, Oral; Adult; Canrenone; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Male; Pregnadienes; Spectrophotometry, Ultraviolet; Spironolactone | 1983 |
Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
Topics: Administration, Oral; Adult; Biological Availability; Canrenone; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Kinetics; Male; Pregnadienes; Spironolactone | 1983 |
Influence of food intake on antihypertensive drugs: spironolactone.
Topics: Adult; Blood Pressure; Canrenone; Creatinine; Female; Food; Heart Rate; Humans; Hypertension; Male; Middle Aged; Potassium; Sodium; Spironolactone | 1983 |
Metabolism of spirolactones by the rat testis in vitro.
Topics: Animals; Biotransformation; Canrenone; Chromatography, High Pressure Liquid; In Vitro Techniques; Male; Rats; Spironolactone; Testis | 1983 |
Clinical pharmacology of diuretics.
Topics: Canrenoic Acid; Canrenone; Diuretics; Ethacrynic Acid; Humans; Hydrochlorothiazide; Intestinal Absorption; Kinetics; Protein Binding; Sodium Chloride Symporter Inhibitors; Spironolactone | 1983 |
Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
Topics: Adult; Canrenone; Female; Fluorometry; Humans; Kinetics; Male; Pregnadienes; Spironolactone; Time Factors | 1983 |
Spironolactones and glomerular filtration.
Topics: Adult; Canrenone; Chromogenic Compounds; Creatinine; Glomerular Filtration Rate; Humans; Spironolactone | 1983 |
Dose-response relationships for spironolactone at steady state.
Topics: Adult; Canrenone; Dose-Response Relationship, Drug; Double-Blind Method; Fludrocortisone; Humans; Male; Middle Aged; Natriuresis; Potassium; Random Allocation; Spironolactone | 1982 |
Cholestyramine and spironolactone and their combination in digitoxin elimination.
Topics: Canrenone; Cholestyramine Resin; Digitoxin; Drug Interactions; Humans; Spironolactone; Time Factors | 1980 |
Importance of the lactonic ring in the activity of steroidal antialdosterones.
Topics: Adrenalectomy; Animals; Canrenoic Acid; Canrenone; Chemical Phenomena; Chemistry; Lactones; Male; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Sodium; Spironolactone; Steroids | 1980 |
[Acetylation of spironolactone, canrenone and 2-methyl-canrenone].
Topics: Acetylation; Animals; Binding, Competitive; Blood Proteins; Canrenone; Humans; In Vitro Techniques; Rats; Rats, Wistar; Receptors, Cell Surface; Spironolactone | 1995 |
High-performance liquid chromatographic determination of spironolactone and its major metabolite canrenone in urine using ultraviolet detection and column-switching.
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Spectrophotometry, Ultraviolet; Spironolactone | 1994 |
Binding of spironolactone metabolites in vivo to renal mineralocorticoid receptors in guinea pigs.
Topics: Aldosterone; Animals; Binding, Competitive; Canrenone; Guinea Pigs; Kidney; Male; Receptors, Mineralocorticoid; Spironolactone | 1994 |
Simultaneous determination of spironolactone and its metabolites in human plasma.
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Osmolar Concentration; Reproducibility of Results; Spectrophotometry, Ultraviolet; Spironolactone | 1996 |
Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.
Topics: Animals; Aorta, Thoracic; Canrenoic Acid; Canrenone; Cardiotonic Agents; Guinea Pigs; In Vitro Techniques; Isotonic Solutions; Muscle, Smooth, Vascular; Ouabain; Potassium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Vasoconstriction | 1996 |
Intoxication due to negative canrenone interference in digoxin drug monitoring.
Topics: Aged; Canrenone; Digoxin; Drug Interactions; Drug Monitoring; Enzyme Multiplied Immunoassay Technique; Fatal Outcome; Humans; Male; Medication Errors; Multiple Organ Failure; Sepsis; Spironolactone | 1999 |
Micromolar concentrations of steroids and of aldosterone antagonists inhibit the outwardly rectifying chloride channel with different kinetics.
Topics: Aldosterone; Anti-Inflammatory Agents; Canrenone; Chloride Channels; Corticosterone; Cytosol; Dose-Response Relationship, Drug; Estradiol; HT29 Cells; Humans; Hydrocortisone; Ion Channel Gating; Kinetics; Lipids; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Progesterone; Spironolactone; Testosterone | 2000 |
Use of partial least-squares regression for multicomponent determinations based on kinetic spectrofluorimetric data. Simultaneous determination of canrenone and spironolactone in urine.
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Regression Analysis; Spectrometry, Fluorescence; Spironolactone | 2000 |
Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.
Topics: Animals; Aorta, Thoracic; Calcium Channel Blockers; Canrenoic Acid; Canrenone; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Potassium Channel Blockers; Potassium Chloride; Rats; Rats, Wistar; Spironolactone | 2000 |
Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
Topics: Anti-Arrhythmia Agents; Canrenone; Chromatography, High Pressure Liquid; Cross Reactions; Digoxin; Diuretics; Drug Interactions; False Negative Reactions; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mineralocorticoid Receptor Antagonists; Prodrugs; Reagent Kits, Diagnostic; Spironolactone | 2002 |
Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
Topics: Canrenoic Acid; Canrenone; Cardiotonic Agents; Digoxin; Drug Interactions; Fluorescence Polarization Immunoassay; Humans; Luminescent Measurements; Mineralocorticoid Receptor Antagonists; Reproducibility of Results; Spironolactone | 2002 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; Endomyocardial Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Spironolactone | 2002 |
Biotransformations of the cardiovascular drugs mexrenone and canrenone.
Topics: Biotransformation; Canrenone; Cardiovascular Agents; Chromatography, High Pressure Liquid; Fermentation; Fungi; Magnetic Resonance Spectroscopy; Molecular Structure; Mortierella; Spironolactone; Stereoisomerism | 2003 |
A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
Topics: Canrenoic Acid; Canrenone; Cardiotonic Agents; Cross Reactions; Digoxin; Drug Interactions; Fluorescence Polarization Immunoassay; Humans; Spironolactone | 2003 |
RELATIONSHIP OF PLASMA ALDADIENE LEVELS AND ANTIMINERALOCORTICOID EFFECTS OF SPIRONOLACTONE IN THE LABORATORY.
Topics: Adrenalectomy; Animals; Blood; Body Fluids; Canrenone; Desoxycorticosterone; Dogs; Natriuresis; Photometry; Plasma; Potassium; Rats; Research; Spironolactone; Urine | 1964 |
Aldosterone enhances renal calcium reabsorption by two types of channels.
Topics: Absorption; Aldosterone; Animals; Biological Transport; Calcium; Calcium Channels, L-Type; Calcium Channels, T-Type; Canrenone; Cycloheximide; Kidney; Kidney Tubules, Distal; Kidney Tubules, Proximal; Kinetics; Membranes; Mineralocorticoid Receptor Antagonists; Protein Synthesis Inhibitors; Rabbits; Second Messenger Systems; Sodium; Spironolactone; Time Factors | 2004 |
Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
Topics: Canrenone; Case-Control Studies; Child; Chromatography, High Pressure Liquid; Drug Stability; Humans; Reference Standards; Reproducibility of Results; Spironolactone; Time Factors | 2006 |
Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
Topics: Blood Chemical Analysis; Canrenone; Chromatography, High Pressure Liquid; Complex Mixtures; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Spironolactone | 2006 |
A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
Topics: Artifacts; Canrenone; Cross Reactions; Digoxin; Enzyme-Linked Immunosorbent Assay; Fluorescence Polarization Immunoassay; Humans; Luminescent Measurements; Nephelometry and Turbidimetry; Reagent Kits, Diagnostic; Sensitivity and Specificity; Spironolactone | 2006 |
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Topics: Canrenoic Acid; Canrenone; Cross Reactions; Digoxin; Drug Interactions; Humans; Immunoassay; Mineralocorticoid Receptor Antagonists; Spironolactone | 2008 |
The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients.
Topics: Animals; Caffeine; Calcium; Calcium Channels, L-Type; Canrenone; Dose-Response Relationship, Drug; Homeostasis; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocytes, Cardiac; Papillary Muscles; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Spironolactone | 2009 |
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Topics: Animals; Bufanolides; Canrenone; Cardiomyopathies; Cardiotonic Agents; Cells, Cultured; Disease Models, Animal; Drug Interactions; Endomyocardial Fibrosis; Fibroblasts; Mineralocorticoid Receptor Antagonists; Myocardium; Nephrectomy; Ouabain; Procollagen; Proline; Rats; Renal Insufficiency; Spironolactone; Tritium; Uremia | 2009 |
Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.
Topics: Aldosterone; Binding, Competitive; Canrenoic Acid; Canrenone; Drug Interactions; Glucuronosyltransferase; Humans; Hymecromone; In Vitro Techniques; Kidney; Microsomes; Microsomes, Liver; Spironolactone | 2010 |
Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples.
Topics: Canrenone; Chromatography, High Pressure Liquid; Furosemide; Humans; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Spironolactone; Tandem Mass Spectrometry | 2010 |
Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
Topics: Anti-Arrhythmia Agents; Canrenoic Acid; Canrenone; Chemistry, Clinical; Cross Reactions; Digoxin; Immunoassay; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
Topics: Biological Assay; Canrenoic Acid; Canrenone; Cardiotonic Agents; Chemistry, Clinical; Cross Reactions; Digoxin; Drug Interactions; Drug Monitoring; Humans; Immunoassay; Mineralocorticoid Receptor Antagonists; Osmolar Concentration; Reagent Kits, Diagnostic; Spironolactone | 2010 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinical Trials; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Molecular Structure; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk; Spironolactone | 2011 |
Incurred sample reanalysis: different evaluation approaches on data obtained for spironolactone and its active metabolite canrenone.
Topics: Canrenone; Female; Humans; Male; Reproducibility of Results; Spironolactone; Therapeutic Equivalency | 2011 |
Canrenone--the principal active metabolite of spironolactone?
Topics: Adult; Canrenone; Dose-Response Relationship, Drug; Humans; Potassium; Sodium; Spironolactone; Young Adult | 1976 |
A diastereoselective synthesis of 7α-nitromethyl steroid derivative and its use for an efficient synthesis of eplerenone.
Topics: Canrenone; Crystallography, X-Ray; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Molecular Structure; Spironolactone; Stereoisomerism | 2012 |
Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
Topics: Canrenoic Acid; Canrenone; Digoxin; Humans; Immunoassay; Luminescent Measurements; Models, Molecular; Spironolactone | 2012 |
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenone; Humans; Hypertension; Inflammation; Insulin Resistance; Mineralocorticoid Receptor Antagonists; Spironolactone | 2014 |
Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
Topics: Animals; Aorta; Arterial Pressure; Bufanolides; Canrenone; Cells, Cultured; Collagen Type I; Endothelin-1; Erythrocytes; Female; Fibrosis; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitroprusside; Pulse Wave Analysis; Rats; Rats, Wistar; Sodium-Potassium-Exchanging ATPase; Spironolactone; Vasodilator Agents | 2015 |
Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Topics: Biotransformation; Canrenone; Cloning, Molecular; Cortodoxone; Cytochrome P-450 CYP11B2; Desoxycorticosterone; Eplerenone; Escherichia coli; Humans; Kinetics; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Recombinant Proteins; Spironolactone; Steroid 11-beta-Hydroxylase; Transcriptional Activation | 2016 |
Simultaneous separation and rapid determination of spironolactone and its metabolite canrenone in different pharmaceutical formulations and urinary matrices by capillary zone electrophoresis.
Topics: Canrenone; Drug Compounding; Electrophoresis, Capillary; Humans; Molecular Conformation; Spironolactone | 2016 |
Signal Enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH
Topics: Canrenone; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Mineralocorticoid Receptor Antagonists; Spectrometry, Mass, Electrospray Ionization; Spironolactone; Tandem Mass Spectrometry | 2017 |
Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
Topics: Canada; Canrenone; Clinical Trials as Topic; Heart Failure; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Russia; Spironolactone; United States | 2017 |
Successive ratio subtraction as a novel manipulation of ratio spectra for quantitative determination of a mixture of furosemide, spironolactone and canrenone.
Topics: Calibration; Canrenone; Furosemide; Reproducibility of Results; Spectrophotometry; Spironolactone | 2018 |
Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma.
Topics: Canrenone; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Furosemide; Humans; Limit of Detection; Linear Models; Reproducibility of Results; Spironolactone; Tablets | 2018 |
Stability-indicating analytical method of quantifying spironolactone and canrenone in dermatological formulations and iontophoretic skin permeation experiments.
Topics: Animals; Canrenone; Dermatologic Agents; Drug Stability; Excipients; Iontophoresis; Limit of Detection; Linear Models; Nanoparticles; Reproducibility of Results; Skin; Skin Absorption; Spironolactone; Swine | 2019 |
The human adrenal gland as a drug metabolizer: First in-vivo evidence for the conversion of steroidal drugs.
Topics: Adrenal Glands; Aged; Canrenone; Cytochrome P-450 CYP11B2; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Steroid 11-beta-Hydroxylase | 2019 |
Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats.
Topics: Animals; Canrenone; Chromatography, Liquid; Delayed-Action Preparations; Fundus Oculi; Intravitreal Injections; Mass Spectrometry; Polyesters; Rats; Rats, Wistar; Retina; Spironolactone; Time Factors; Tissue Distribution; Tomography, Optical Coherence | 2020 |
Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.
Topics: Animals; Biomarkers; Canrenone; Drugs, Chinese Herbal; Herb-Drug Interactions; Male; Rats; Rats, Sprague-Dawley; Spironolactone | 2020 |